Research programme: EP4 receptor agonists - Merck FrosstAlternative Names: L-902688
Latest Information Update: 20 Oct 2009
At a glance
- Originator Merck Frosst
- Mechanism of Action Prostaglandin E4 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 27 Sep 2006 Preclinical trials in Glaucoma in Canada (Ophthalmic)